View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 16, 2020

Germany awards €750m to BioNTech and CureVac for Covid-19 vaccines

The German Government has granted a total of up to €750m in funding to domestic firms BioNTech and CureVac to support the work on their respective Covid-19 vaccine candidates.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BioNTech, which partnered with Pfizer and Fosun Pharma on the BNT162 Covid-19 vaccine programme, will receive €375m from the German Federal Ministry of Education and Research (BMBF).

The funding will go towards boosting vaccine development and manufacturing capabilities in Germany while expanding the number of volunteers in late-stage clinical trials.

BioNTech CEO and co-founder Ugur Sahin said: “We are grateful for the significant support from the BMBF, which is helping us to provide a safe and effective vaccine as soon as possible following regulatory approval.

“The funding is an important contribution to accelerate the development and scaling-up of our Covid-19 vaccine manufacturing capacities in Germany.”

The company plans to use the funding for costs associated with its BNT162 Covid-19 vaccine programme. The aim is to speed-up the clinical evaluation and potential marketing approval.

Pfizer will independently fund its share of development costs for BNT162 without this or other government funding.

Enrolment is ongoing for a Phase II / III trial of the Covid-19 vaccine candidate, with more than 28,000 participants recruited at sites in the US, Brazil, Argentina and Europe.

Meanwhile, the BMBF agreed to provide CureVac with up to €252m to support the development of the company’s Covid-19 vaccine candidate.

Alongside the development of the vaccine candidate, CureVac will use the funds to expand its production capacity. Payments are dependent on predefined milestones.

The company expects funding of up to €103m in 2020, as well as €149m in 2021.

According to Reuters, the German ministry was in discussions to provide funding to a third company, IDT Biologika.

Related Companies

Free Report

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy